If you or a loved one has taken Tysabri and are concerned about progressive multifocal leukoencephalopathy (PML), you likely have questions about risk factors, monitoring, and next steps. The history of medical safety communication has long emphasized the importance of informed patient-provider dialogue. This page outlines key discussion points to help you prepare for a productive conversation with your doctor.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three factors that increase risk: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors must be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML includes progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The FDA Adverse Event Reporting System (FAERS) lists adverse events most frequently associated with Tysabri, including fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they reflect the spectrum of neurological symptoms that may overlap with early PML signs.
Mechanistically, Tysabri is a monoclonal antibody that binds to alpha-4 integrin on lymphocytes, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system but also impairs immune surveillance against JCV. Under normal conditions, JCV is controlled by the immune system; however, when T-cell trafficking is blocked, the virus can reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The latency between Tysabri exposure and PML onset can range from months to several years, with risk increasing after two years of continuous therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates enrollment in the TOUCH Prescribing Program, a restricted distribution system designed to ensure patients understand risks and are monitored (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers adequately communicated the risk, particularly regarding the cumulative effect of treatment duration and prior immunosuppressant use.
For patients in Arizona who have developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Arizona, the statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. Given that PML symptoms may initially be subtle and mistaken for multiple sclerosis relapse, the discovery date can be complex. The timeline between Tysabri exposure and documented harm is critical: PML typically develops after months to years of treatment, and the diagnosis may be delayed. Patients should consult with an attorney experienced in pharmaceutical litigation to assess whether their claim falls within the statutory window. Factors such as the date of last Tysabri infusion, date of PML diagnosis, and any prior warnings received will influence the analysis. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a requirement for patient monitoring. The clinical presentation of PML can be insidious, and the mechanistic link through immune modulation is established. For affected individuals in Arizona, understanding the statute of limitations and the adequacy of warnings is essential when considering legal action.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. For PML, which may have a delayed onset and subtle symptoms, the discovery date can be complex. It is crucial to consult an attorney promptly to evaluate your specific timeline.
The prescribing information identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors increase the likelihood of PML, and patients should be monitored accordingly (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.